Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

Researchers say ability to see for the first time previously hidden indicators of MS disease progression is an important advance.

As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...

Researchers have developed new AI approach to select chemical compounds potentially effective for treating tuburculosis.

PROTACs have helped redefine what may be possible in drug discovery. By harnessing the ubiquitin-proteasome system to ...

This eBook explores how researchers can move beyond correlation and towards mechanism in microbiome research—from preserving physiologically relevant microbial communities to directly measuring ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.

Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) ...

Synthetic organizers provide a way to control formation of kidney organoids as more reliable models for studying disease and ...

To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.

As instruments grow faster, leaders say clinical impact will depend on trust, standards, data, and assays built for real ...